ProCE Banner Activity

PERSEUS: Primary Analysis of Phase III Trial With VRd ± Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Eligible for ASCT

Conference Coverage

Primary results from the pivotal PERSEUS trial conducted in transplant-eligible patients with NDMM showed that D-VRd induction, ASCT, D-VRd consolidation, and D-R maintenance significantly reduced the risk of disease progression or death compared with the same regimen but without daratumumab.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.